DOV PHARMACEUTICAL GETS NASDAQ LETTER

Shares of DOV Pharmaceutical Inc. slipped to a fresh 52-week low after the biopharmaceutical company said it received a letter from the Nasdaq that it failed to comply with several listing requirements. The company's market value fell below $50 million for 10 straight business days, and total assets and total revenue also fell below $50 million.
Business Week